| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Epithelial Pathobiology Group, Centre for Immunology and Cancer Research, University of Queensland Department of Medicine, Princess Alexandra Hospital, Brisbane, Queensland, 4102 Australia
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In the initial phase of differentiation, keratinocytes undergo irreversible growth arrest. This growth arrest is associated with an irreversible down-regulation of genes associated with proliferation such as E2F1 (1 , 2) , cdk1 (3) , or p53 (4) . The down-regulation of these genes seems to be a complex process mediated by transcriptional (5, 6, 7) and posttranscriptional mechanisms (2) . E2F is a transcription factor complex that is required for the initiation of DNA synthesis (8) . In its active form, "free" E2F binds its cognate response element and induces gene expression. In its inactive form, E2F is complexed with inhibitory pocket proteins. During growth arrest, E2F activity is lost or inhibited, which results in the decrease of mRNA expression for E2F-responsive genes such as cdk1 and E2F1 (5, 6, 7) . In the instance of cdk1, this down-regulation is also mediated by the activation of a transcriptional repressor (9) . Combined, these data indicate that keratinocyte growth arrest is mediated by the loss of trans-activators and the induction of trans-repressors. These data take on more significance when contrasted with keratinocyte-derived squamous carcinoma cell lines. These cell lines are generally resistant to normal growth-inhibitory stimuli (3 , 4) and are characterized by a failure to down-regulate cdk1 and E2F1 mRNA expression (1 , 3) . The growth inhibitor insensitivity seems to correlate with the inability to regulate the expression of proliferation genes in an appropriate fashion.
The induction of growth arrest is followed by the induction of genes required for squamous differentiation-specific functions (e.g., maintenance of the impermeable barrier). The barrier function of the epidermis is bestowed, in large part, by the formation of the cross-linked envelope (10) . The cross-linked envelope is formed by the transglutaminase-catalyzed cross-linking of precursor proteins such as cornifin, involucrin, and fillagrin (10 , 11) . The activation of this differentiation pathway seems to be regulated by several transcription factors such as activator protein 1 (12) , activator protein 2 (13) , cAMP-responsive element binding protein/activating transcription factor3 , and Skn1a/i (14) . Thus, the activation of the later phases of the epithelial squamous differentiation pathway is also associated with the coordination of transcriptional events.
Transcriptional regulation is a complex process that is associated with the interaction of the basal transcription machinery with positive/negative upstream regulatory factors. This process has been complicated by the reports that alterations in the tertiary structure of the DNA such as nucleosomal integrity also affect transcription (for a review, see Refs. 15, 16, 17, 18 ). The nucleosomal integrity is regulated by the association of the core histones (H2A, H2B, H3, and H4) and the linker histone H1. This nucleosomal integrity is maintained, in part, by the acetylation status of the core histones (15, 16, 17, 18) . In the hypoacetylated state, a tight nucleosomal structure is maintained (15, 16, 17, 18) that is nonpermissive for transcription (15, 16, 17, 18) . When the core histones are acetylated, the nucleosomal integrity is relaxed, and the DNA becomes permissive to transcriptional regulation (15, 16, 17, 18) . The acetylation status of the histones is governed by the combined activities of the histone acetylases and histone deacetylases (15, 16, 17, 18) ; consequently, the disruption of these enzymes has been implicated in alterations in transcriptional regulation (19, 20, 21) . This has been further supported by recent studies in which various transcription factors such as c-myc or hormone receptors exist as DNA-bound complexes with histone acetylase or deacetylase enzymes (for a review, see Ref. 17 ).
Given that the regulation of squamous differentiation involves the coordination of various transcriptional activities, and because histone deacetylase inhibitors may induce global changes in chromatin structure (and presumably in transcription), we initiated a series of experiments to: (a) determine the consequences of altering histone acetylation status on the regulation of the squamous differentiation pathway in normal human keratinocytes; and (b) determine the potential of inhibiting histone deacetylases as a basis for treating skin cancers. Earlier studies have used the histone deacetylase inhibitor sodium butyrate to alter histone acetylation as well as induce epithelial differentiation. Sodium butyrate has previously been reported to induce differentiation and growth arrest in keratinocytes (22 , 23) . However, sodium butyrate is also known to alter protein kinase C activity and mitochondrial function (24 , 25) . Thus, a definitive association between histone acetylation status and differentiation status is not possible. Recently, specific histone deacetylase inhibitors (TSA4 and trapoxin) have been synthesized (25) . These compounds now allow a more detailed examination of the role of histone acetylation status in various biological systems.
The present study demonstrates that both sodium butyrate and TSA induce growth arrest and differentiation of normal human keratinocytes that are characterized by a coordinated decrease in the expression of a proliferation marker gene (cdk1) and the induction of a differentiation specific marker gene (TG1). In contrast, these agents also induce growth arrest in a squamous carcinoma cell line, but without activating the squamous differentiation pathway. Our data suggest that TSA may have potential as a topical treatment of squamous carcinomas of the skin.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
RNA Isolation and Analysis.
Total RNA was isolated from HEK cultures using the chaotropic agent Trizol (Life Technologies, Inc.), and single-stranded cDNA was synthesized (1)
. Expression of transglutaminase type I (TG1), cdk1, and actin was detected by PCR using specific primers (1
, 9)
under linear conditions with respect to the cycle number. PCR reactions were fractionated on a 1% agarose gel, blotted to nylon, and UV fixed. Blots were then prehybridized, hybridized (28)
, and probed with the appropriate 32P-labeled oligonucleotide. The final stringency for washing the blots used in 0.5x SSC, 0.1% SDS at 45°C for 10 min. Blots were then exposed to Kodak XAR5 film or phosphorimager screens. Quantitation was performed using Imagequant software from Molecular Biosciences (New South Wales, Australia).
Histone Isolation and Immunodetection of Acetylated Histone H4.
Keratinocytes were either left untreated or treated with NaB (1 mM) or TSA (300 nM) for varying times. In one experiment, histones were isolated from confluent differentiated HEKs. Histones were also isolated from untreated SCC25 cells or from SCC25 cells treated with NaB (3 mM) or TSA (300 nM). At varying times after treatment, cells were trypsinized, and histones were isolated by using established techniques (29)
. Histone proteins were quantified by the Bio-Rad protein assay. Each sample (5 µg) was then dried down in a centrifugal vacuum dryer (Radiometer Pacific), and the samples were resuspended in protein sample buffer (1)
, boiled, and run on a 7.5% SDS-PAGE. Proteins were then transferred to nitrocellulose (Amersham), and the acetylated histone H4 was detected with a rabbit polyclonal antibody (Upstate Biotechnology Inc.) against acetylated histone H4 (1:2000 dilution in 3% skim milk powder in PBS containing 0.1% Tween 20 (vol/vol)). Visualization was by means of enhanced chemiluminescence detection (Amersham). The specificity of the antibody was confirmed by the detection of purified histone H4 (Boehringer Mannheim) run on the same gel.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. We next examined whether the growth inhibition induced by NaB was reversible or irreversible. This point is of interest because agents capable of inducing irreversible growth arrest can also induce differentiation, whereas agents such as TGF-ß1, which induce a reversible growth arrest, do not induce differentiation in keratinocytes (3)
. Therefore, NaB was added to keratinocytes, and the keratinocytes were rinsed thoroughly with fresh media at various times thereafter and allowed to continue their incubation for 48 h. Fig. 1B
clearly shows that to obtain growth inhibition, NaB had to be continuously present. Combined, these data indicate that the effects of butyrate are mediated through a pathway that requires continuous activation by butyrate. Examination of the dose dependency of butyrate action (Fig. 1C)
indicates that it has an EC50 value of approximately 0.5 mM and is maximal at 1 mM
|
|
. Proliferating keratinocytes were growth inhibited by TSA with an EC50 value of approximately 120 nM and a maximal effective concentration of 300 nM. A similar dose-response profile has been reported for the induction of tissue-type plasminogen activator in human endothelial cells (33)
. Similar to butyrate, TSA was not toxic at any of these doses (<95% viability as estimated by trypan blue dye exclusion)
Treatment of HEKs with either NaB or TSA was accompanied by alterations in keratinocyte morphology (data not shown). After a 5-day treatment with 1 mM NaB or 300 nM TSA, keratinocytes took on a flattened appearance reminiscent of the squamous differentiated phenotype. This prompted us to examine the effects of NaB or TSA on the expression of genes specific for proliferation (cdk1) or differentiation (TG1). The expression of cdk1 mRNA was reduced within 8 h and was maximally reduced by 24 h with both NaB or TSA (Fig. 2, A and B)
. The level of cdk1 mRNA remained low for up to 5 days after NaB treatment (Fig. 2A)
, whereas in the TSA-treated cells, the cdk1 mRNA levels returned to basal levels by 48 h (Fig. 2B)
. This rebound in cdk1 mRNA levels in TSA-treated cells was not associated with a return to proliferation (see Fig. 1D
). A similar response to both NaB and TSA was observed with another proliferation-associated gene, E2F1 (data not shown). Treatment with NaB (Fig. 2A)
or TSA (Fig. 2B)
was associated with an increase in the differentiation-specific marker TG1. This was a late event that occurred 2–5 days after NaB or TSA treatment. These data indicate that both NaB and TSA can induce the growth arrest and differentiation of keratinocytes, which is associated with a decrease in cdk1 (albeit transiently in the TSA-treated cells) followed by an increase in TG1 mRNA levels
|
. In the first instance, proliferating HEKs had minimal levels of acetylated H4. Furthermore, when cells differentiated at confluence, there was no change in the levels of acetylated H4. More surprising was the observation that both NaB and TSA treatment of HEKs resulted in a rapid accumulation of acetylated H4 by 8 h that returned to basal levels 48 h after treatment. These data are consistent with the inhibition of histone deacetylase by NaB or TSA. However, these data suggest that even in the continued presence of inhibitor, there is only a transient accumulation of acetylated histone H4.
Histone Deacetylase Inhibitors Are Potent Inhibitors of Squamous Carcinoma Cell Growth.
Previous studies with keratinocyte-derived squamous carcinoma cells have shown they are unable to respond to normal growth inhibitors such as phorbol esters, IFN-
, confluence (1
, 3)
, or TGF-ß1 (31)
. We examined the effects of NaB and TSA on a well-characterized squamous carcinoma cell line, SCC25 (Fig. 3)
. The responses of the SCC25 cell line in response to NaB or TSA were similar to those of HEKs. Butyrate (3 mM) caused a time-dependent decrease in DNA synthesis that was maximal by 48 h (Fig. 3A)
and reversible (Fig. 3B)
. An examination of the dose-dependent growth arrest by NaB indicated that SCC25 cells were less responsive to NaB (an EC50 value of approximately 1 mM and a maximal effective dose of 3 mM) than the HEKs (an EC50 value of approximately 0.5 mM and a maximal dose of 1 mM). TSA treatment decreased DNA synthesis (Fig. 3D)
in an apparently irreversible (Fig. 3E)
and dose-dependent manner (Fig. 3F)
. TSA treatment of SCC25 cells had an EC50 value of 100 nM and a maximal effective dose of 300 nM (Fig. 3F)
. These values are similar to those of normal keratinocytes; similarly, there was no toxicity (by dye exclusion test) at any of the concentrations tested (data not shown). These data are significant because with few exceptions, inducers of growth arrest in keratinocytes do not normally inhibit the growth of keratinocyte-derived carcinoma cells. The inhibition of DNA synthesis by NaB and TSA was not restricted to the SCC25 cells because another keratinocyte-derived squamous carcinoma cell line, SCC15, was also growth inhibited by NaB or TSA (Table 1)
. Furthermore, we also examined the effects of NaB or TSA on normal HEKs expressing the HPV16 E6 and E7 proteins. The expression of the E6 and E7 genes in these cells was confirmed by RT-PCR analysis (Ref. 1
; data not shown). These cells exhibit deregulated growth characteristics but were still growth inhibited by NaB or TSA (Table 1)
. These data established that the growth inhibition induced by TSA and NaB also occurred in another SCC cell line and in HEKs with deregulated growth
|
. In contrast to HEKs, the treatment of SCC25 cells did not result in the initiation of the differentiation program. SCC25 cells are a partially differentiated squamous carcinoma cell line and consequently express TG1. Treatment of SCC25 cells with either NaB or TSA resulted in a decrease in cdk1 mRNA expression in SCC25 cells (Fig. 4, A and B)
. However, both NaB and TSA also resulted in a decrease in the differentiation-specific marker gene, TG1. These data demonstrate that treatment of the SCC25 cells with histone deacetylase inhibitors does not result in the reinstatement of a normal squamous differentiation program. Similar to the HEKs, NaB and TSA treatment resulted only in a transient accumulation of acetylated histone H4 (Fig. 4C)
. In the instance of NaB treatment, histone acetylation was maximal by 24 h and had decreased to basal levels by 48 h (Fig. 4C)
. TSA treatment, on the other hand, resulted in a rapid accumulation of acetylated histone H4 by 8 h that decreased to basal levels by 24 h (Fig. 4C)
|
).
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This study provides strong evidence supporting the trial of TSA in the treatment of topical neoplasms such as SCCs. For instance, in vitro studies with TSA indicated that it produces an irreversible growth arrest (at least in the short term) in SCC cells. Previous studies using butyrate and various structural analogues of butyrate have proved disappointing for a number of reasons. The most significant of these is the short half-life of butyrate when given systemically (approximately 6 min; Ref. 29 ). In this study we show that NaB is relatively stable in vitro in keratinocytes. This is most clearly shown by the observation that keratinocytes and SCC25 cells must be exposed to NaB continuously to mediate growth arrest. If NaB is required continuously to mediate growth inhibition, then it must be biologically active for at least 48 h in keratinocyte cultures. However, because the action of NaB seems to be reversible in nature, we believe that TSA may be a more favorable compound to trial in the treatment of topical neoplasms. TSA induces an apparently irreversible growth arrest, and given the lipophilicity of TSA, it may be possible to deliver high concentrations of TSA specifically to the skin lesion.
The present study clearly shows that treatment of normal or transformed keratinocytes with histone deacetylase inhibitors initiates a growth-inhibitory pathway that is dissimilar to that of normal squamous differentiation. Superficially, the effects of NaB and TSA on normal HEKs seem to be similar to those of other differentiation-inducing agents (e.g., TPA or IFN-; Refs. 1
and 3
) in that growth arrest is accompanied by decreases in cdk1 mRNA expression and the induction of TG1 expression. However, closer examination of normal keratinocytes suggested differences between the induction of squamous differentiation mediated by other agents and the responses associated with TSA or NaB treatment. For instance, in contrast to phorbol ester-treated keratinocytes, the induction of TG1 in NaB- or TSA-treated keratinocytes was only moderate (2.5–3.5-fold compared with 10-fold for TPA-treated cells; Ref. 2
). Furthermore, the reduction in cdk1 mRNA in TSA-treated cells was only transient and did not correlate with the apparent irreversibility of action of TSA or DNA synthesis data. This is in contrast to the tight correlation between cdk1 mRNA expression and DNA synthesis reported for keratinocytes undergoing growth arrest in response to senescence, confluence, or TGF-ß1, TPA, or IFN- treatment (3
, 26) . Our studies with the SCC25 cells also support a novel mechanism of growth inhibition for NaB and TSA. Both TSA and NaB induced a similar dose- and time-dependent growth arrest in the absence of an increase in the differentiation-specific marker gene TG1 in squamous carcinoma cells. This difference was significant at two levels: (a) the SCC25 cells are resistant to other growth-inhibitory stimuli that we have tested (1)
; and (b) the growth arrest was not associated with the induction of differentiation. Combined, these data would suggest that the mechanism of action of TSA and NaB in keratinocytes is not mediated by the activation of the normal squamous differentiation pathway.
A possible explanation for the effects of NaB or TSA may be derived from the observation that the inhibition of histone deacetylases leads to hyperacetylation of histones (as exemplified by H4 in this study) and an alteration in chromatin structure. Such an alteration in the chromatin may be perceived by the cell as akin to a DNA-damaging event (as postulated in Ref. 25) . In this circumstance, normal keratinocytes may undergo growth arrest/retardation. Supporting this proposition are reports that substituting the four lysines in the amino-terminal tail of H4 with glutamate results in a histone with the same characteristics as tetra-acetylated H4, which, in yeast, results in a G2-M-phase block (15 , 32) . A G1- and a G2-M-phase block has previously been reported for keratinocytes and colonic epithelial cells treated with NaB (23 , 24) . However, the mechanism by which these checkpoints are executed is unknown. Arguing against this proposition is the observation that most carcinoma cells have lost the ability to undergo growth inhibition in response to DNA-damaging events, suggesting that a novel pathway of growth inhibition would have to be present in the carcinoma cells.
The present study demonstrates that the induction of growth arrest in normal keratinocytes and the inhibition of tumorigenicity in keratinocyte-derived carcinoma cells are not simply due to the accumulation of acetylated histones and the deregulation of gene expression. This is supported by the observation that TG1 mRNA is induced in normal keratinocytes and repressed in carcinoma cells in response to both NaB or TSA. On one hand, it was found that acetylated histone H4 accumulated rapidly in both normal and cancer cells after NaB or TSA treatment. However, in all instances, this accumulation was transient. Evidence suggesting that histone H4 acetylation was not directly required for growth arrest stems from the observation that in HEKs, both NaB and TSA cause the induction of TG1 at a time at which the H4 acetylation has returned to basal levels. Furthermore, the reversibility of TSA action in SCC25 cells after an 8-h treatment (maximal H4 acetylation) and the reversibility of NaB in HEKs at 24 h after treatment (H4 acetylation was decreased) is not consistent with a direct role of histone acetylation in this process. However, these data are consistent with histone hyperacetylation initiating a cascade of events that ultimately triggers growth arrest and modulation of TG1 mRNA expression. The transient accumulation of acetylated histones after NaB or TSA treatment has not been reported before and contrasts with that reported in human endothelial cells (33) . Although the mechanism underlying the transient hyperacetylation in keratinocytes is unknown, it is possible that NaB or TSA may decrease the activity/expression of the histone acetylases or may increase the activity of histone deacetylases such that the inhibitor concentrations are no longer effective.
Although this study focuses primarily on biological end points such as growth and differentiation, it raises some interesting observations on how changes in histone acetylation status (exemplified by H4 acetylation) may affect normal cellular processes. Previous reports on how histone acetylation may be implicated in the control of transcription suggest a complicated model in which histone acetylation bestows transcriptional competence to a gene (16) . It is clear that the appropriate regulation of histone acetylation is essential to normal cellular physiology. For example, histone H3 and H4 mutants, which were unable to be acetylated, proved to be lethal mutations (32) . Furthermore, the acetylation of histones is essential for DNA replication (15) . Although histone acetylation is essential for cell survival, it is only recently that we have become aware of some of the mechanisms by which it mediates its effects. For instance, recent studies have provided compelling evidence that positive or negative transcriptional regulation by established transcription factors such as Mad/Max, E2F, YY1, or members of the steroid/thyroid receptor superfamilies requires interactions with either histone acetylases or deacetylases (34, 35, 36, 37, 38, 39) . Thus, the transcription factors remain the major regulators of transcriptional control, whereas the acetylase and deacetylase enzymes contribute to the activation or repressive functions of the DNA-bound transcription factor. There is some evidence in the HEKs that this may occur because both the cdk1 and TG1 promoters may be accessible to normal transcriptional activators or repressors due to the acetylation of the histones. This explanation, however, would not be consistent with the presumed general activating properties of acetylated histones because cdk1 mRNA is decreased and TG1 is increased. Furthermore, TG1 is increased in normal keratinocytes and repressed in the carcinoma cells. A recent study reported that the inhibition of cellular proliferation may be mediated by the binding of Rb to a histone deacetylase that results in transcriptional repression of the E2F transcription factor and, consequently, growth arrest (39) . This may provide an explanation for the growth inhibition we observed in both HEKs and SCC25 cells because both the HEKs and the SCC25 cells contain E2F (1) , and the cdk1 gene is an E2F-responsive gene (5) , and the level of cdk1 mRNA was decreased in response to NaB or TSA in both HEKs and SCC25 cells.
In conclusion, the present study demonstrates that NaB and TSA are potent growth inhibitors for both normal HEKs and transformed keratinocytes. We also show that TSA may have potential as a topical therapeutic for use in epidermal neoplasms.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by the Queensland Cancer Fund (95/QCFN003G), The Mayne Bequest Fund, The Australian Research Council (96/ARCS016G), and The Garnett Passe and Rodney Williams Memorial Foundation. A. D. was funded by an Australian National Health and Medical Research Council Centre for Immunology and Cancer Research predoctoral scholarship, and C. P. was funded by an Australian National Health and Medical Research Council Centre for Immunology and Cancer Research Honours Studentship. 
2 To whom requests for reprints should be addressed, at University of Queensland Department of Medicine, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland, 4102, Australia. Phone: 617-3240-5936; Fax: 617-3240-5946; E-mail: NSaunders{at}medicine.pa.uq.edu.au
3 A. Medvedev, N. A. Saunders, A. Chistokhina, H. Matsuura, and A. M. Jetten. Regulation of transglutaminase type I: identification of DNA elements involved in transcriptional control, submitted for publication.
4 The abbreviations used are: TSA, trichostatin A; HEK, human epidermal keratinocyte; HPV, human papillomavirus; TGF, transforming growth factor; RT-PCR, reverse transcription-PCR; TPA, 12-O-tetradecanoylphorbol-13-acetate; SCC, squamous cell carcinoma.
Received 7/28/98. Accepted 11/11/98.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
: antagonism by retinoic acid and transforming growth factor ß1. J. Biol. Chem., 269: 2016-2022, 1994. in vitro. Am. J. Respir. Cell Mol. Biol., 11: 147-152, 1994.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  T. S. Cunneen, R. M. Conway, and M. C. Madigan In Vitro Effects of Histone Deacetylase Inhibitors and Mitomycin C on Tenon Capsule Fibroblasts and Conjunctival Melanoma Cells Arch Ophthalmol, April 1, 2009; 127(4): 414 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Gu, J. Ding, X. Wang, R. L. de Kluyver, N. A. Saunders, I. H. Frazer, and K.-N. Zhao Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation Nucleic Acids Res., July 9, 2007; (2007) gkm496v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Duan, J. Friedman, L. Nottingham, Z. Chen, G. Ara, and C. Van Waes Nuclear factor-{kappa}B p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 Mol. Cancer Ther., January 1, 2007; 6(1): 37 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Honma, M. Stubbs, I. Collins, P. Workman, W. Aherne, and F. M. Watt Identification of Novel Keratinocyte Differentiation Modulating Compounds by High-Throughput Screening J Biomol Screen, December 1, 2006; 11(8): 977 - 984. [Abstract] [PDF]
|
|
|
|
 |
|
 N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer. Ann. Thorac. Surg., March 1, 2006; 81(3): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Lee and B. T. Zhu Inhibition of DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols Carcinogenesis, February 1, 2006; 27(2): 269 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Johnson, N. Maronian, and J. Vieira Activation of Kaposi's Sarcoma-Associated Herpesvirus Lytic Gene Expression during Epithelial Differentiation J. Virol., November 1, 2005; 79(21): 13769 - 13777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-N. Zhao, W. Gu, N. X. Fang, N. A. Saunders, and I. H. Frazer Gene Codon Composition Determines Differentiation-Dependent Expression of a Viral Capsid Gene in Keratinocytes In Vitro and In Vivo Mol. Cell. Biol., October 1, 2005; 25(19): 8643 - 8655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Lee, J.-Y. Shim, and B. T. Zhu Mechanisms for the Inhibition of DNA Methyltransferases by Tea Catechins and Bioflavonoids Mol. Pharmacol., October 1, 2005; 68(4): 1018 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Altmann, R. B. Schulz, G. Glensch, H. Eskerski, S. Zitzmann, M. Eisenhut, and U. Haberkorn Effects of Pax8 and TTF-1 Thyroid Transcription Factor Gene Transfer in Hepatoma Cells: Imaging of Functional Protein-Protein Interaction and Iodide Uptake J. Nucl. Med., May 1, 2005; 46(5): 831 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sanderson, G. W. Taylor, E. O. Aboagye, J. P. Alao, J. R. Latigo, R. C. Coombes, and D. M. Vigushin PLASMA PHARMACOKINETICS AND METABOLISM OF THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A AFTER INTRAPERITONEAL ADMINISTRATION TO MICE Drug Metab. Dispos., October 1, 2004; 32(10): 1132 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Chung, A.-J. Wang, and L.-F. Yao Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy Mol. Cancer Ther., March 1, 2004; 3(3): 317 - 325. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Takai, J. C. Desmond, T. Kumagai, D. Gui, J. W. Said, S. Whittaker, I. Miyakawa, and H. P. Koeffler Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells Clin. Cancer Res., February 1, 2004; 10(3): 1141 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Fang, Y. Wang, N. Ai, Z. Hou, Y. Sun, H. Lu, W. Welsh, and C. S. Yang Tea Polyphenol (-)-Epigallocatechin-3-Gallate Inhibits DNA Methyltransferase and Reactivates Methylation-Silenced Genes in Cancer Cell Lines Cancer Res., November 15, 2003; 63(22): 7563 - 7570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grassi, P. Maccaroni, R. Meyer, H. Kaiser, E. D'Ambrosio, E. Pascale, M. Grassi, A. Kuhn, P. Di Nardo, R. Kandolf, et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87 Carcinogenesis, October 1, 2003; 24(10): 1625 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cimini, M. Mattiuzzo, L. Torosantucci, and F. Degrassi Histone Hyperacetylation in Mitosis Prevents Sister Chromatid Separation and Produces Chromosome Segregation Defects Mol. Biol. Cell, September 1, 2003; 14(9): 3821 - 3833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Graziani, L. Tentori, I. Portarena, M. Vergati, and P. Navarra Valproic Acid Increases the Stimulatory Effect of Estrogens on Proliferation of Human Endometrial Adenocarcinoma Cells Endocrinology, July 1, 2003; 144(7): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Elaut, G. Torok, M. Vinken, G. Laus, P. Papeleu, D. Tourwe, and V. Rogiers Major Phase I Biotransformation Pathways of Trichostatin A in Rat Hepatocytes and in Rat and Human Liver Microsomes Drug Metab. Dispos., December 1, 2002; 30(12): 1320 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Patnaik, E. K. Rowinsky, M. A. Villalona, L. A. Hammond, C. D. Britten, L. L. Siu, A. Goetz, S. A. Felton, S. Burton, F. H. Valone, et al. A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies Clin. Cancer Res., July 1, 2002; 8(7): 2142 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yu, Z. S. Guo, M. G. Marcu, L. Neckers, D. M. Nguyen, G. A. Chen, and D. S. Schrump Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228 J Natl Cancer Inst, April 3, 2002; 94(7): 504 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Burgess, S. Pavey, R. Warrener, L.-J. K. Hunter, T. J. Piva, E. A. Musgrove, N. Saunders, P. G. Parsons, and B. G. Gabrielli Up-Regulation of p21WAF1/CIP1 by Histone Deacetylase Inhibitors Reduces Their Cytotoxicity Mol. Pharmacol., October 1, 2001; 60(4): 828 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Butler, Y. Webb, D. B. Agus, B. Higgins, T. R. Tolentino, M. C. Kutko, M. P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, et al. Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, an Inhibitor of Histone Deacetylase Clin. Cancer Res., April 1, 2001; 7(4): 962 - 970. [Abstract] [Full Text]
|
|
|
|
|
|
C. Nervi, U. Borello, F. Fazi, V. Buffa, P. G. Pelicci, and G. Cossu Inhibition of Histone Deacetylase Activity by Trichostatin A Modulates Gene Expression during Mouse Embryogenesis without Apparent Toxicity Cancer Res., February 1, 2001; 61(4): 1247 - 1249. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Maeda, M. Towatari, H. Kosugi, and H. Saito Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood, December 1, 2000; 96(12): 3847 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Koyama, M. Adachi, M. Sekiya, M. Takekawa, and K. Imai Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis Blood, August 15, 2000; 96(4): 1490 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qiu, A. Burgess, D. P. Fairlie, H. Leonard, P. G. Parsons, and B. G. Gabrielli Histone Deacetylase Inhibitors Trigger a G2 Checkpoint in Normal Cells That Is Defective in Tumor Cells Mol. Biol. Cell, June 1, 2000; 11(6): 2069 - 2083. [Abstract] [Full Text]
|
|
|
|
 |
|
 Q. Zhou, Z. K. Melkoumian, A. Lucktong, M. Moniwa, J. R. Davie, and J. S. Strobl Rapid Induction of Histone Hyperacetylation and Cellular Differentiation in Human Breast Tumor Cell Lines following Degradation of Histone Deacetylase-1 J. Biol. Chem., November 3, 2000; 275(45): 35256 - 35263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Diamond and A. Gutierrez-Hartmann The Pit-1beta Domain Dictates Active Repression and Alteration of Histone Acetylation of the Proximal Prolactin Promoter J. Biol. Chem., September 29, 2000; 275(40): 30977 - 30986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Brinkmann, A. L. Dahler, C. Popa, M. M. Serewko, P. G. Parsons, B. G. Gabrielli, A. J. Burgess, and N. A. Saunders Histone Hyperacetylation Induced by Histone Deacetylase Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human Dermal Fibroblasts J. Biol. Chem., June 15, 2001; 276(25): 22491 - 22499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar, and P. S. Klein Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen J. Biol. Chem., September 21, 2001; 276(39): 36734 - 36741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Derjuga, C. Richard, M. Crosato, P. S. Wright, L. Chalifour, J. Valdez, A. Barraso, H. A. Crissman, W. Nishioka, E. M. Bradbury, et al. Expression of p21Waf1/Cip1 and Cyclin D1 Is Increased in Butyrate-resistant HeLa Cells J. Biol. Chem., October 5, 2001; 276(41): 37815 - 37820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hu, Z. Chen, T. Fredrickson, Y. Zhu, R. Kirkpatrick, G.-F. Zhang, K. Johanson, C.-M. Sung, R. Liu, and J. Winkler Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcription Repressor J. Biol. Chem., May 12, 2000; 275(20): 15254 - 15264. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
